Covalent modification of the oncogene product Mdm2 by the ubiquitin-related protein SUMO1 protects it from ubiquitination and enhances its E3 ligase activity towards p53 in vitro. Disappearance of ...
It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor ...
These two pivotal studies will be multicenter, open-label, randomized, registrational Phase III studies: first one is to evaluate the efficacy and safety of APG-2449 versus platinum-based ...
The company has built a rich pipeline of innovative drug candidates that includes novel, highly potent Bcl-2 and dual ...
欢迎关注凯莱英药闻2024年9月25日，Kymera Therapeutics在欧洲皮肤病和性病学会 (EADV) 大会上公布了临床前在研药物KT-621的最新研究数据。KT-621 是一种强效、选择性口服 STAT6 ...
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget 10: 8226-43, 2015 Abbas Manji G, Singer S, Koff A, and Schwartz ...
【导读】结直肠癌(CRC)是全球癌症相关死亡率的第二大原因，而p53作为一种被广泛认可的肿瘤抑制因子，促进了CRC的发展。USP36属于去泛素化酶家族，参与多种癌症的进展。然而，在结直肠癌中USP36调控p53信号通路的潜在分子机制尚不清楚。9月29 ...
7don MSN
经济观察网 记者 瞿依贤 北京时间9月27日，美国食品药品监督管理局（FDA）肿瘤药物专家咨询委员会（ODAC）的一场会议结束，历时9个小时。这场会议的讨论结果可能让国内外的PD-1类药物市场大变。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback